Physician profile
Michael S Mccloskey
NPI 1437627502
$2,225.09
in general payments reported to CMS, 2019-2025
27 companies · $2,208 in 2025
The $2,208 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.22 · 2025: $2,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $463.31 | 2025 | |
| Lilly USA, LLC | $294.72 | 2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $274.85 | 2025 | Airsupra, Farxiga, Breztri |
| Phathom Pharmaceuticals, INC. | $159.72 | 2025 | Voquezna |
| Exact Sciences Corporation | $140.28 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $99.66 | 2025 | Ozempic |
| Glaxosmithkline, LLC. | $93.46 | 2025 | Bexsero, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $66.71 | 2025 | Auvelity |
| Pfizer INC. | $65.59 | 2025 | |
| Sumitomo Pharma America, INC. | $58.91 | 2025 | Gemtesa |
| Ars Pharmaceuticals Operations, INC. | $58.68 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.50 | 2025 | Jardiance |
| Renalytix Ai, INC. | $49.62 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Otsuka America Pharmaceutical, INC. | $46.91 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $41.30 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $36.01 | 2025 | Flucelvax, Fluad |
| Edwards Lifesciences Corporation | $35.79 | 2025 | |
| Sanofi Pasteur INC. | $23.92 | 2025 | |
| Shield Therapeutics INC | $23.86 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.63 | 2025 | |
| Optinose US, INC. | $19.17 | 2025 | |
| Ibsa Pharma INC. | $17.33 | 2025 | Tirosint, Licart, Flector |
| Hologic Sales and Service, LLC | $17.22 | 2023 | Aptima |
| Amgen INC. | $16.27 | 2025 | Evenity |
| Merck Sharp & Dohme LLC | $15.66 | 2025 | Gardasil 9, Enflonsia, Capvaxive |
| Lundbeck LLC | $14.53 | 2025 | Rexulti |
| Astellas Pharma US INC | $14.48 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccloskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.